Home > Insider Trading > Filing (0000919574-21-000168)

Filing Details

Accession Number:: 0000919574-21-000168
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-01-08 20:31:40
Reporting Period:: 2021-01-06

Accepted Time:: 2021-01-08 20:31:40
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1372514	Eyegate Pharmaceuticals Inc	EYEG	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1601086	Armistice Capital, Llc	510 Madison Avenue, 7Th Floor New York, NY 10022	Yes	No	Yes	No
1633584	Ltd. Fund Master Capital Armistice	C/O Dms Corporate Services Ltd. 20 Genesis Close, P.o. Box 314 Grand Cayman E9 KY1-1104	Yes	No	Yes	No
1706140	Steven Boyd	C/O Armistice Capital, Llc 510 Madison Avenue, 7Th Floor New York NY 10022	Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-01-06	1,531,101	$5.23	3,346,601	No	4	P	Direct
Common Stock	Acquisiton	2021-01-06	0	$0.00	3,346,601	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrants	Acquisiton	2021-01-06	1,531,101	$0.00	1,531,101	$5.23
Common Stock	Warrants	Acquisiton	2021-01-06	0	$0.00	0	$5.23

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,531,101	2021-07-06	2025-01-06	No	4	P	Direct
1,531,101	2021-07-06	2025-01-06	No	4	P	Indirect

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Warrants	$3.13	2020-04-02	2024-10-02	600,000	600,000	Direct
Common Stock	Warrants	$3.13	2020-04-02	2024-10-02	0	600,000	Indirect
Common Stock	Warrants	$0.32	2018-04-17	2023-04-17	41,666	41,666	Direct
Common Stock	Warrants	$0.32	2018-04-17	2023-04-17	0	41,666	Indirect
Common Stock	Warrants	$0.32	2018-04-17	2023-04-17	364,583	364,583	Direct
Common Stock	Warrants	$0.32	2018-04-17	2023-04-17	0	364,583	Indirect
Common Stock	Warrants	$1.50	2017-06-14	2022-06-14	133,333	133,333	Direct
Common Stock	Warrants	$1.50	2017-06-14	2022-06-14	0	133,333	Indirect
Common Stock	Warrants	$0.32	2018-04-17	2023-04-17	1,062,500	1,062,500	Direct
Common Stock	Warrants	$0.32	2018-04-17	2023-04-17	0	1,062,500	Indirect
Common Stock	Series C Convertible Preferred Stock	$0.32	2018-04-17		852,500	852,500	Direct
Common Stock	Series C Convertible Preferred Stock	$0.32	2018-04-17		0	852,500	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2024-10-02	600,000	600,000	Direct
2024-10-02	0	600,000	Indirect
2023-04-17	41,666	41,666	Direct
2023-04-17	0	41,666	Indirect
2023-04-17	364,583	364,583	Direct
2023-04-17	0	364,583	Indirect
2022-06-14	133,333	133,333	Direct
2022-06-14	0	133,333	Indirect
2023-04-17	1,062,500	1,062,500	Direct
2023-04-17	0	1,062,500	Indirect
	852,500	852,500	Direct
	0	852,500	Indirect

Footnotes

The reported securities of EyeGate Pharmaceuticals, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital.
(Continued from Footnote 1) Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
On January 5, 2021, the Issuer and the Master Fund entered into a securities purchase agreement (the "Securities Purchase Agreement") pursuant to which the Master Fund acquired from the Issuer in a private placement on the January 6, 2021 closing date: (i) 1,531,101 shares of the Issuer's common stock, $0.01 par value (collectively, the "Shares"); and (ii) warrants to purchase up to 1,531,101 Shares with an exercise price of $5.225 per Share (collectively, the "Warrants"). The aggregate subscription amount paid by the Master Fund for the Shares and Warrants acquired by it pursuant to the Securities Purchase Agreement was $8,000,002.73.
These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 9.99% beneficial owner of the Shares following such exercise.
These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the Shares following such exercise.
The Series C Convertible Preferred Stock has no expiration date and is convertible at any time at the option of the Master Fund.